Tafinlar

Tafinlar is a prescription medicine containing dabrafenib used to treat certain cancers with specific genetic mutations. Doctors prescribe it to treat cancers that carry a specific genetic mutation called BRAF V600. It belongs to a class of medicines called BRAF kinase inhibitors, which work by blocking abnormal signals that drive cancer cell growth and spread. Tafinlar is typically used either alone or in combination with the targeted therapy trametinib (Mekinist) to treat certain metastatic or advanced cancers. Because the medicine works only in tumors with a BRAF mutation, patients usually undergo an FDA-approved genetic test before starting treatment.

Tafinlar (dabrafenib) is FDA-approved for the treatment of certain cancers with a BRAF V600 mutation.

FDA-approved uses of Tafinlar include:

• Unresectable or metastatic melanoma with BRAF V600K or V600E mutations.
• Adjuvant treatment of melanoma after surgical removal to reduce the risk of recurrence (with trametinib).
• Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation (with trametinib).
• Anaplastic thyroid cancer with BRAF V600E mutation that has spread and has no satisfactory treatment options (in combination with trametinib).
• Unresectable or metastatic solid tumors with BRAF V600E mutation in adults and children aged 6 years and older who don’t have satisfactory alternative treatments (with trametinib).
• Low-grade glioma in pediatric patients (1 year and older) with BRAF V600E mutation that requires systemic therapy (with trametinib).

• Tafinlar (dabrafenib) is a targeted cancer medication that belongs to the BRAF inhibitor class.
• It is used to treat cancers with a BRAF V600 mutation, including melanoma, non-small cell lung cancer, thyroid cancer, and certain other solid tumors.
• It works by blocking abnormal BRAF proteins that allow cancer cells to grow and spread.
• Tafinlar is often prescribed in combination with trametinib (Mekinist) to improve treatment outcomes.
• It is typically taken twice daily as oral capsules on an empty stomach.
• Genetic testing for the BRAF mutation is required before starting treatment to ensure the therapy is appropriate.

Tafinlar targets the BRAF protein, a kinase in the RAS-RAF-MEK-ERK signaling pathway that regulates cell growth and survival.

In some cancers, mutations in the BRAF gene—especially the V600E mutation—keep this protein permanently activated. This leads to uncontrolled cell division and tumor growth.

Dabrafenib works by:

1. Inhibiting the mutated BRAF kinase
2. Blocking abnormal cell signaling
3. Slowing or stopping cancer cell growth

When used with trametinib, the treatment blocks two steps of the same pathway (BRAF and MEK), which can improve tumor control and reduce resistance to therapy.

• Tafinlar capsules should be used only in patients whose tumors test positive for a BRAF V600 mutation, as confirmed by an FDA-approved test, before starting treatment.
• This medicine may increase the risk of new skin cancers, including cutaneous squamous cell carcinoma. Regular skin examinations are recommended during treatment and for several months after stopping the medicine.
• Fever (pyrexia) is a common side effect and may sometimes be severe. Patients should contact their healthcare provider if they develop a high fever, chills, or dehydration.
• Tafinlar capsules can cause serious bleeding problems, including bleeding in the brain or stomach. Seek immediate medical help if unusual bleeding, black stools, or severe headaches occur.
• The medication may affect heart function, particularly when used with trametinib. Doctors may monitor heart function during treatment.
• Vision problems such as blurred vision, eye pain, or redness can occur and may indicate serious eye conditions that require medical evaluation.
• Tafinlar may cause high blood sugar (hyperglycemia), especially in patients with diabetes. Blood glucose levels may need regular monitoring.
• The medicine can increase the risk of serious skin reactions, including severe rashes or peeling skin. Patients should report any significant changes in skin to their doctor.
• Liver function tests may be required during treatment because the medication can affect liver enzymes.
• Tafinlar can harm an unborn baby, so effective birth control should be used during treatment and for a period after the last dose.
• Breastfeeding is not recommended during treatment and for some time after stopping the medication because it may pass into breast milk.
• Patients should inform their doctor about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.

• Secondary malignancies: Tafinlar may increase the risk of developing new cancers, including cutaneous squamous cell carcinoma and other non-cutaneous malignancies. Patients should be monitored regularly for new skin lesions or other signs of cancer.
• Severe fever reactions (especially with trametinib): High fever and fever-related complications can occur, particularly when Tafinlar is used in combination with trametinib. These reactions may require dose interruption or medical management.
• Serious skin reactions: Severe skin reactions, including Stevens-Johnson syndrome (SJS) and other serious dermatologic conditions, have been reported. Treatment should be discontinued if severe skin reactions occur.
• Eye disorders: Tafinlar may increase the risk of eye problems such as uveitis or retinal vein occlusion, which can lead to vision changes. Patients should report any eye pain, redness, or vision disturbances promptly.
• Hemolytic anemia in G6PD deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia while using Tafinlar and should be monitored closely.

Like many cancer medications, Tafinlar can cause side effects. Some are mild and manageable, whereas others may require medical attention.

Tafinlar is contraindicated in patients who:

• Have hypersensitivity to dabrafenib or any of its components.

Tafinlar should not be used in patients with wild-type BRAF tumors because it may increase tumor growth.

The dosage and administration guide for Tafinlar:

• Tafinlar should be taken exactly as prescribed by your doctor.
• Take the medication twice daily at the same time each day.
• Take the capsules on an empty stomach. Take it at least 1 hour before a meal or at least 2 hours after eating.
• Swallow the capsules whole with water.
• Pregnant women should not handle a broken or crushed capsule.

In case of a Tafinlar overdose, contact the Poison Control Center at 1-800-222-1222 immediately. No specific antidote exists; supportive treatment is recommended.

If you are taking Tafinlar, follow the regimen as directed. If you miss a dose of Tafinlar, follow a simple set of instructions:

• If a dose is missed, take it as soon as possible unless the next scheduled dose is within 6 hours. In that case, skip the missed dose.
• Do not double your Tafinlar dose, as this can lead to severe consequences.

Follow these Tafinlar storage guidelines to maintain the medication properly:

• Store the medicine at room temperature (20°C-25°C or 68°F-77°F).
• Keep Tafinlar capsules in their original packaging to protect them from moisture.
• Do not split or crush the capsules.
• Keep the capsules in a dry place.
• Do not store the medicine in the bathroom because humidity can degrade it.
• Keep out of reach of children and pets.

The following medications may interact with Tafinlar and may require dose adjustment or monitoring. Consult your healthcare professional for the complete list of Tafinlar interactions.

• Abemaciclib
• Aficamten
• Atogepant
• Atorvastatin
• Atrasentan
• Avacopan
• Avanafil
• Avapritinib
• Axitinib
• Bedaquiline
• Butorphanol
• Bosutinib
• CYP3A4/CYP2C8 inducers and inhibitors

If Tafinlar is unavailable or not suitable, use the following Tafinlar alternatives after consulting your doctor.

• Vemurafenib
• Encorafenib
• Trametinib
• Cobimetinib
• Binimetinib
• Pembrolizumab
• Nivolumab

Tafinlar is a targeted cancer therapy that can be expensive, especially for patients who require long-term treatment. In the United States, the cost of Tafinlar may vary by pharmacy pricing, dosage, and insurance coverage. Because treatment may last for months or longer, many patients seek ways to lower medication costs.

You may be able to buy Tafinlar online from Canada through Polar Bear Meds, which can help eligible patients access their prescribed medication at more affordable prices through licensed Canadian and international pharmacy partners. Patients may also benefit from pharmacy savings programs or other cost-assistance options to lower out-of-pocket costs.

Tafinlar can be expensive when purchased from many local U.S. pharmacies, particularly for patients without insurance coverage. Polar Bear Meds helps patients access their prescribed medications at more affordable prices by sourcing them through licensed Canadian and international pharmacy partners.

When you buy Tafinlar online from Canada through Polar Bear Meds, you benefit from competitive pricing for genuine prescription medication, along with exclusive savings, including coupon codes for additional discounts on your first order.

Ordering is simple—once you submit a valid prescription, our team works with licensed pharmacy partners to process your order and arrange safe delivery. Medications are shipped via reliable courier services such as Xpress Post, with delivery typically within 3–5 business days.

Polar Bear Meds also prioritizes patient safety, secure ordering, and responsive customer support to ensure a smooth, reliable process. For patients seeking an affordable and convenient way to buy Tafinlar online from Canada, Polar Bear Meds offers a trusted solution.

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea
• https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors
• https://www.drugs.com/tafinlar.html